Aging is a highly complex biological process and the leading risk factor for chronic diseases that make up the bulk of morbidity, mortality, and health care costs. By 2030, one in every five Americans will be over the age of 65, a fact that increases the urgency in addressing this field.
Within just the last few years, anti-aging has swiftly progressed from the academic to the commercial research space. It has gained credibility, financial backing and interest from major pharmaceutical and biotechnology companies, and from other technology sectors.
Commercial recognition that cellular aging can be inhibited or slowed as a whole, rather than simply treating diseases of aging as individual indications, has led to a paradigm shift. The race is on to find broad-acting therapeutic interventions that can both treat and delay the onset of common age-related diseases.
At Rejenevie™, we are developing a strategy to extend wellness and healthy living and redefine the molecular process of aging through world-class science and reproducible results. Our rigorous approach seeks to generate new knowledge and to capture and analyze clinical data that demonstrate we are achieving our goals.
The Rejenevie™ vision of healthcare targets the fundamental drivers of the complex process of aging, rather than the individual diseases as they occur. Our revolutionary approach uses the hematopoietic and immune systems as a model to identify differential relationships between youthful and aged systems, providing a way to isolate restorative factors that target key causal aging mechanisms. The result is new therapies and interventions that can prevent or delay aging-related diseases.